title: ProAlgaZyme subfraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites.
abstract: BACKGROUND
  Previously, we reported that ProAlgaZyme (PAZ) and its biologically active fraction improved plasma lipids in hypercholesterolemic hamsters, by significantly increasing the high density lipoprotein cholesterol (HDL-C) while reducing non-HDL cholesterol and the ratio of total cholesterol/HDL-C. Moreover, hepatic mRNA expression of genes involved in HDL/reverse cholesterol transport were significantly increased, while cholesteryl ester transfer protein (CETP) expression was partially inhibited. In the current study, we investigated the therapeutic efficacy of the biologically active fraction of PAZ (BaP) on the plasma lipid and plasma metabolomic profiles in diet induced hypercholesterolemic hamsters.
  
  
  METHODS
  Fifty male Golden Syrian hamsters were fed a high fat diet for 4 weeks prior to randomization into 6 groups, based on the number of days they received subsequent treatment. Thus animals in T0, T3, T7, T10, T14, and T21 groups received BaP for 0, 3, 7, 10, 14, and 21 days, respectively, as their drinking fluid. Plasma lipids were assayed enzymatically, while real-time reverse transcriptase polymerase chain reaction (RT-PCR) provided the transcription levels of the Apolipoprotein (Apo) A1 gene. The plasma metabolomic profile was determined using 1H nuclear magnetic resonance (NMR) spectroscopy in conjunction with multivariate analysis.
  
  
  RESULTS
  Plasma HDL-C was significantly increased in T3 (P < 0.05) and T21 (P < 0.001), while non-HDL cholesterol was significantly reduced in T3, T7, T10 (P < 0.001) and T14, T21 (P < 0.01). Moreover, the ratio of total cholesterol/HDL-C was significantly lower in all BaP treated groups (P < 0.001) as compared with T0. Quantitative RT-PCR showed an increase in Apo A1 expression in T10 (3-fold) and T21 (6-fold) groups. NMR data followed by multivariate analysis showed a clear separation between T0 and T21 groups, indicating a difference in their metabolomic profiles. Plasma concentrations of metabolites associated with a risk for atherosclerosis and cardiovascular disease, including choline, phosphocholine, glycerol-phosphocholine, betaine and carnitine metabolites were significantly lower in the T21 group.
  
  
  CONCLUSIONS
  Treatment with BaP significantly improved the plasma lipid profile by increasing HDL-C and lowering non-HDL cholesterol. In addition, BaP potentially improved the plasma metabolomic profile by reducing the concentration of key metabolites associated with risk for atherosclerosis and cardiovascular disease.
authors: Nutrition and Food Science, 3009 Science Hall, Wayne State University, Detroit, MI 48202, USA. sgupta@wayne.edu.
authors: Andreea
authors: A
authors: Geamanu
authors: Arvind
authors: A
authors: Goja
authors: Nadia
authors: N
authors: Saadat
authors: Pramod
authors: P
authors: Khosla
authors: Smiti V
authors: SV
authors: Gupta
references: Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-8
references: 1342260
references: Cardiovasc Res. 2013 Mar 15;97(4):642-52
references: 23241314
references: Annu Rev Nutr. 1998;18:39-61
references: 9706218
references: Am J Physiol Gastrointest Liver Physiol. 2012 Jul 15;303(2):G263-74
references: 22628034
references: Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):182-95
references: 22258901
references: Br J Nutr. 2009 Sep;102(6):842-7
references: 19527552
references: EMBO Mol Med. 2010 Mar;2(3):79-89
references: 20201031
references: Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12511-6
references: 16895997
references: Br J Nutr. 2007 Apr;97(4):758-63
references: 17349089
references: J Steroid Biochem Mol Biol. 1992 Dec;43(8):779-804
references: 22217824
references: Anal Chem. 2006 Jul 1;78(13):4430-42
references: 16808451
references: Physiol Rev. 1983 Oct;63(4):1420-80
references: 6361812
references: J Lipid Res. 2010 Jun;51(6):1546-53
references: 19965573
references: Br J Nutr. 2009 Dec;102(12):1728-39
references: 19728895
references: Nature. 2011 Apr 7;472(7341):57-63
references: 21475195
references: Mol Divers. 2006 May;10(2):187-205
references: 16802062
references: Expert Opin Biol Ther. 2013 May;13(5):631-42
references: 23350815
references: Lipids Health Dis. 2007 Sep 05;6:20
references: 17803818
references: Exp Gerontol. 2011 Oct;46(10):787-93
references: 21741463
references: Mol Biosyst. 2005 Jul;1(2):166-75
references: 16880980
references: J Biol Chem. 2005 Dec 30;280(52):42508-14
references: 16239221
references: Adv Food Nutr Res. 2012;66:75-145
references: 22909979
references: J Mol Cell Cardiol. 2013 Feb;55:2-11
references: 23231771
references: Toxicol Appl Pharmacol. 2009 Feb 1;234(3):314-25
references: 19073202
references: Clin Biochem. 2011 Mar;44(4):293-9
references: 21167146
references: Am J Clin Nutr. 2006 Sep;84(3):531-9
references: 16960166
references: Circulation. 2002 May 7;105(18):2159-65
references: 11994249
references: Chem Res Toxicol. 2008 Jan;21(1):9-27
references: 18171018
references: Atherosclerosis. 2009 Sep;206(1):127-33
references: 19324361
references: J Nutr. 2005 Mar;135(3):492-8
references: 15735083
references: J Agric Food Chem. 2011 Jun 22;59(12):6790-7
references: 21561085
references: J Nutr. 2007 Apr;137(4):923-9
references: 17374655
references: Am J Cardiol. 1998 Feb 26;81(4A):18B-25B
references: 9526809
references: J Agric Food Chem. 2011 Mar 9;59(5):2069-76
references: 21302942
references: Nat Med. 2013 May;19(5):576-85
references: 23563705